ETON vs PATH · rev $39.0M vs P/E 19, rev $1.61B
Eton Pharmaceuticals Inc (ETON) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Eton Pharmaceuticals Inc (ETON) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ETON revenue for 2024-12-31 was $39.0M. Net income was -$3.8M. Revenue was up 23.3% from 2023-12-31 to 2024-12-31. ETON currently screens at market cap $797.9M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ETON currently screens at market cap $797.9M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ETON and PATH stock pages for the full models.
Not investment advice.